thalidomide has been researched along with Sarcoma in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 9.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 5.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 5.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| "Activity against colorectal cancer cells was dependent on target antigen expression, but independent of KRAS status and FcγRIIIa genotype." | 1.37 | Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. ( Adams, M; Bartlett, JB; Lu, L; Parton, A; Schafer, P; Wu, L, 2011) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 1.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganjoo, K | 1 |
| Jacobs, C | 1 |
| Wu, L | 1 |
| Parton, A | 1 |
| Lu, L | 1 |
| Adams, M | 1 |
| Schafer, P | 1 |
| Bartlett, JB | 1 |
| ROE, FJ | 1 |
| MITCHLEY, BC | 1 |
| Dalle, JH | 1 |
| Leblond, P | 1 |
| Decouvelaere, A | 1 |
| Yakoub-Agha, I | 1 |
| Preudhomme, C | 1 |
| Nelken, B | 1 |
| Mazingue, F | 1 |
| Yi-Shin Kuo, D | 1 |
| Timmins, P | 1 |
| Blank, SV | 1 |
| Fields, AL | 1 |
| Goldberg, GL | 1 |
| Murgo, A | 1 |
| Christos, P | 1 |
| Wadler, S | 1 |
| Runowicz, CD | 1 |
| Balasubramanian, L | 1 |
| Evens, AM | 1 |
| von Mehren, M | 1 |
| Abidi, MH | 1 |
| Tove, I | 1 |
| Ibrahim, RB | 1 |
| Maria, D | 1 |
| Peres, E | 1 |
2 reviews available for thalidomide and Sarcoma
| Article | Year |
|---|---|
Antiangiogenesis agents in the treatment of soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Intracellular Signaling Peptides and Protein | 2010 |
Antiangiogenesis agents in the treatment of soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Intracellular Signaling Peptides and Protein | 2010 |
Targeting angiogenesis for the treatment of sarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Neovascularizatio | 2006 |
Targeting angiogenesis for the treatment of sarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Neovascularizatio | 2006 |
1 trial available for thalidomide and Sarcoma
| Article | Year |
|---|---|
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Topics: Administration, Oral; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; Neoplasm Recurrence | 2006 |
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Topics: Administration, Oral; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; Neoplasm Recurrence | 2006 |
5 other studies available for thalidomide and Sarcoma
| Article | Year |
|---|---|
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent | 2011 |
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent | 2011 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Child, Preschool; Humans; Leukemia-Lymphoma, Adu | 2003 |
Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Child, Preschool; Humans; Leukemia-Lymphoma, Adu | 2003 |
New therapeutics for soft-tissue sarcomas in adults.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizum | 2007 |
New therapeutics for soft-tissue sarcomas in adults.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizum | 2007 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2007 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2007 |